Neuroendocrine Tumor Research Advances
Moving in New England Journal of Medicine, bioRxiv, Gut, Nature Reviews Cancer.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Neuroendocrine Tumor Research Advances
Newest first · last 60 days
Obexelimab significantly delays disease flares and reduces glucocorticoid use in IgG4-related disease, with a hazard ratio of 0.44 and fewer flares compared to placebo.
- 2 cites
Proteomic analysis of 267 neuroendocrine carcinomas reveals five subtypes with distinct molecular and therapeutic vulnerabilities, including NAD+ dependency in subtype H.
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4